

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NOVEN PHARMACEUTICALS, INC. and MYLAN
PHARMACEUTICALS, INC.,
Petitioners,

v.

NOVARTIS AG and LTS LOHMANN THERAPIE-SYSTEME
AG,
Patent Owner.

Case IPR2014-00550
Patent No. 6,335,031

**PETITIONER MYLAN'S MOTION TO
WITHDRAW AS COUNSEL AND SUBSTITUTE NEW COUNSEL**

I. RELIEF REQUESTED

Pursuant to 37 C.F.R. § 42.10(e), and as authorized by the Board via an email dated November 13, 2015 (*see* 37 C.F.R. § 42.20(b)), counsel for Co-Petitioner, Mylan Pharmaceuticals, Inc. (“Mylan”), respectfully requests authorization to withdraw as counsel for Mylan in this *inter partes* review proceeding.

II. STATEMENT OF REASONS FOR SUBSTITUTION OF COUNSEL


Mylan wishes for new counsel, Steven W. Parmelee (Reg. No. 31,990) and Michael T. Rosato (Reg. No. 52,182) to be designated as lead and back-up counsel, respectively, and represent Mylan going forward in this proceeding. Petitioner’s new counsel meet the requirements of the 37 C.F.R. § 42.10(c) as registered practitioners.

No extension of time will be needed upon grant of this Motion, the Final Written Decision having been issued September 28, 2015. It is believed that granting this Motion will not hinder the economy, the integrity of the patent system, the efficient administration of the Office, or the ability of the Office to timely complete this proceeding. *See* 35 U.S.C. § 316(b).). Patent Owner and Co-Petitioner, Noven Pharmaceuticals, Inc. have indicated in emails dated November 13, 2015 that they do not oppose this Motion.

An executed updated Power of Attorney and updated Mandatory Notices under 37 C.F.R. § 42.8(b)(3) are being filed concurrently.

Respectfully submitted,

Date: Nov. 16, 2015



Joseph M. Reisman, Lead Counsel
Reg. No. 43,878

CERTIFICATE OF SERVICE

I certify that the foregoing Petitioner's Motion to Withdraw as Counsel and Substitute New Counsel was served on this 16th day of November, 2015, on Co-Petitioner Noven Pharmaceuticals, Inc., and the Patent Owner at the correspondence addresses as follows:

CO-PETITIONER NOVEN PHARMACEUTICALS, INC.:

Steven J. Lee
Michael K. Levy
Christopher Coulson
KENYON & KENTON LLP
slee@kenyon.com
mlevy@kenyon.com
ccoulson@kenyon.com

PATENT OWNER:

Raymond R. Mandra, Esquire
Nicholas N. Kallas, Esquire
Charlotte Jacobsen, Esquire
Fitzpatrick, Cella, Harper & Scinto
1290 Avenue of the Americas
New York, New York 10104-3800
ExelonPatchIPR@fchs.com

Respectfully submitted,

Date: Nov. 16, 2015



Joseph M. Reisman, Lead Counsel
Reg. No. 43,878